Literature DB >> 32897465

Frequency of mismatch repair protein deficiency and PD-L1 in high-grade gliomas in adolescents and young adults (AYA).

Ghadeer Almuhaisen1, Yazan Alhalaseh2, Razan Mansour3, Amer Abu-Shanab3, Sura Al-Ghnimat4, Maysa Al-Hussaini5.   

Abstract

Central nervous system tumors in adolescents and young adults (AYA) are rarely reported in the literature. The association with cancer predisposition syndrome is not established. Programmed death ligand 1 (PD-L1) can predict the potential response of patients to immunotherapy. A link between mismatch repair protein deficiency (MMRP-D) and response to immunotherapy is established. P53 is reported to be positive in MMRD-D cases. We aim to investigate the frequency of MMRP-D in AYA with high-grade glioma and any potential association with PD-L1. A total of 96 cases were tested including 49 (51.0%) cases of glioblastoma. Six cases (6.25%) were MMRP-D, 17 (17.7%) were PD-L1 positive, mostly in grade IV tumors (8.7% in grade III compared to 26% in grade IV, p value = 0.027), and 69 (71.9%) were P3 positive. None of the MMRP-D cases expressed PD-L1. P53-positive cases were mostly MMRP proficient (n = 67; 74.4%, p value 0.051). Fourteen cases (28.7%) were positive for both PD-L1 and P53, while p53-positive grade IV tumors were mostly associated with negative PD-L1 (n = 29, 58%, p value = 0.043). MMRP deficiency does not appear to be prevalent in high-grade glioma in AYA. Expression of PD-L1 in a quarter of cases might suggest a role for immunotherapy in high-grade glioma.

Entities:  

Keywords:  Adolescents and young adults; Central nervous system tumors; Glioblastoma; High-grade glioma; Mismatch repair protein; Mismatch repair protein deficiency; PD-L1

Mesh:

Substances:

Year:  2020        PMID: 32897465     DOI: 10.1007/s10014-020-00379-7

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  1 in total

1.  Immunochemistry screening for Lynch syndrome in colorectal adenocarcinoma using an initial two antibody panel can replace a four antibody panel.

Authors:  Toni O'Regan; Kai Chau; Michael Tatton; Tania Smith; Susan Parry; Ian Bissett
Journal:  N Z Med J       Date:  2013-09-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.